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Abstract 
Background: Cerebral malaria (CM) is a fatal complication of Plasmodium infection, mostly affecting children under 
the age of five in the sub-Saharan African region. CM pathogenesis remains incompletely understood, although 
sequestered infected red blood cells, inflammatory cells aggregating in the cerebral blood vessels, and the microvesi-
cles (MV) that they release in the circulation, have been implicated. Plasma MV numbers increase in CM patients and 
in the murine model, where blocking their release, genetically or pharmacologically, protects against brain pathology, 
suggesting a role of MV in CM neuropathogenesis. In this work, the microRNA (miRNA) cargo of MV is defined for the 
first time during experimental CM with the overarching hypothesis that this characterization could help understand 
CM pathogenesis.
Results: The change in abundance of miRNA was studied following infection of CBA mice with Plasmodium berghei 
ANKA strain (causing experimental CM), and Plasmodium yoelii, which causes severe malaria without cerebral compli-
cations, termed non-CM (NCM). miRNA expression was analyzed using microarrays to compare MV from healthy (NI) 
and CM mice, yielding several miRNA of interest. The differential expression profiles of these selected miRNA (miR-
146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV, MV-free plasma, 
and brain tissue by quantitative reverse transcription PCR (RT-qPCR). Two miRNA—miR-146a and miR-193b—were 
confirmed as differentially abundant in MV from CM mice, compared with NCM and NI mice. These miRNA have been 
shown to play various roles in inflammation, and their dysregulation during CM may be critical for triggering the neu-
rological syndrome via regulation of their potential downstream targets.
Conclusions: These data suggest that, in the mouse model at least, miRNA may have a regulatory role in the patho-
genesis of severe malaria.
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Background
Malaria is a devastating infectious disease transmitted 
to vertebrate hosts by the bite of Plasmodium-infected 
female Anopheles mosquitoes [1]. Malaria remains a sub-
stantial problem affecting humans today, with approxi-
mately half of the world’s population at risk. Every year, 
around 200 million people are infected by Plasmodium 
falciparum alone worldwide [2]. Severe malaria is most 
commonly caused by infection with P. falciparum, and 
cerebral malaria (CM) is the most severe manifestation 
of malaria infection. CM is a syndrome characterized by 
unarousable coma and unconsciousness, often leading to 
death, or the occurrence of neurological sequelae in sur-
vivors [3]. Approximately 1% of individuals with malaria 
infection develop CM; however, the reason for this is 
currently unknown. The pathology of this syndrome is 
still incompletely understood, as the existing hypotheses 
cannot fully explain all manifestations and clinical signs 
of CM [4]. Other manifestations of severe malaria can 
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result in severe anaemia and respiratory distress, termed 
here non-cerebral severe malaria (NCM) [2]. Current 
treatment options for CM—that is, anti-malarial medi-
cations combined with immediate intensive care—have 
an 80–85% success rate. However, this is not the case in 
many parts of Africa, where there is increasing levels of 
drug resistance and, in some cases, insufficient access to 
adequate hospital care [5]. In fact, despite successful pre-
vention, persisting neurological sequelae and long-term 
impairments are present in 25% of paediatric CM cases 
[6]. Therefore, further research into the pathology, pro-
gression, and treatment is essential in the prevention and 
elimination of malaria.
Of recent interest is the role that microvesicles (MV) 
play in the pathogenesis of CM both as markers of sever-
ity and effectors. Plasma MV are submicron vesicles 
(diameters of 200–1000  nm) released from most cell 
types in the microvasculature, including those involved 
in the pathogenesis of CM, such as platelets, erythro-
cytes, endothelial cells (EC), and leucocytes [7]. They 
form through the budding of the plasma membrane and 
take with them cytoplasmic proteins, lipids, and nucleic 
acids, as well as surface antigens from the cell of origin. 
Consequently, they are present in the circulation and can 
bind to target cells, propagating biological signals and 
participating in cell–cell communication [8]. While cir-
culating MV play a role in maintaining homoeostasis at 
normal physiological levels [9], imbalances in their num-
bers have been shown to be associated with pathophysi-
ological conditions [7]. During CM, higher levels of MV 
correlate with the presence of neurological symptoms, 
increased disease severity, and coma depth in human 
patients [10, 11] and the murine model [7, 12, 13], while 
in NCM infections, the same significant increase is not 
observed [12, 13]. In addition, blocking the production of 
MV, genetically [12] or pharmacologically [14], is associ-
ated with protection against the development of experi-
mental CM. In mice, MV accumulate within the brain 
microvessels of infected but not healthy recipient mice, 
following adoptive transfer [13]. Analysis of MV, protein, 
lipid, and nucleic acid content provides a strong basis for 
studies to understand their biology and pathophysiology 
[15, 16]. In disease states, MV derived from the injured 
organ likely contain valuable biomarkers, including 
miRNA, for determining the site, type, and extent of dis-
ease pathology [17].
miRNA are small, single-stranded non-coding RNA 
that control more than 30% of protein-coding genes, 
through post-transcriptional regulation of targeted 
gene expression and RNA silencing [18]. miRNA are 
known to play key regulatory roles in numerous bio-
logical processes, including cell proliferation, develop-
ment, differentiation, and apoptosis [19]. miRNA were 
first characterized within circulating plasma vesicles 
by Hunter et al. [20]. Further to this, miRNA contained 
within MV were shown to be transferred to target cells 
through the circulation, suggesting that the biological 
effect of cells may, at least partially, depend on MV-shut-
tled miRNA [21].
miRNA have been shown to be dysregulated in a range 
of parasitic diseases [22]. Specifically, in malaria infec-
tions within mammalian hosts, several studies have 
explored miRNA changes before and after Plasmo-
dium infection in different tissues, including liver and 
brain [23–26], and within circulating extracellular vesi-
cles—both MV and exosomes [27–29]. Studies using the 
murine model have investigated the effect of Plasmo-
dium infection on miRNA signatures within these tis-
sues and plasma, and found that miR-16 and miR-451 
decrease in abundance, while miR-27a and miR-150 
increase in response to infection, and that blocking some 
of these miRNA confers protection to those mice. In con-
trast, miR-451 is increased in extracellular vesicles from 
infected red blood cells [27]. These changes in miRNA 
abundance are reversed following anti-malarial treatment 
[30–32]. These studies suggest that miRNA could be 
involved in the protective immune response or resistance 
against malarial infection, as well as in CM pathogen-
esis, depending on their downstream targets and abun-
dance during infection. In addition, there is evidence of 
the impact that interactions between parasite, host, and 
vector can have on miRNA abundance during malarial 
transmission [33–36].
Despite these studies, an unbiased high-throughput 
characterization of miRNA abundance in MV during CM 
has not yet been carried out. This study examines the 
abundance of miRNA carried within plasma MV during 
experimental CM and NCM, as well as in non-infected 
(NI) mice. MV miRNA are then compared to those cir-
culating in MV-free plasma and expressed in brain tis-
sue, showing that, following infection, specific changes 
are observed in the three types of samples. These changes 
provide potential novel avenues of research into further 
understanding the pathogenesis of severe malaria with a 
particular focus on CM, in order to harness this informa-
tion for therapeutic purposes.
Methods
Mice
7–10-week-old CBA mice were obtained from the Ani-
mal Resource Centre (Perth) and housed under path-
ogen-free conditions, as per approved protocols of the 
University of Sydney Animal Ethics Committee (proto-
col number 2015/832 and 2013/5317). For experimen-
tal comparisons, three biological groups of mice were 
used: non-infected (NI), CM caused by infection with 
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the Plasmodium berghei ANKA strain, and NCM caused 
by Plasmodium yoelii infection. As previously described, 
CBA mice are susceptible to P. berghei infection and suc-
cumb to CM during the neurological phase, between day 
6 and day 14 post-infection (p.i.) [37]. Mice infected with 
P. yoelii survived beyond this point and display severe 
anaemia in the 3rd week after infection.
Plasmodium inoculation
All infections were initiated by intraperitoneal injection 
of 1 × 106 P. berghei or P. yoelii-parasitized red blood cells 
(pRBCs), as previously described [38]. Parasitaemia was 
monitored by counting pRBCs in Diff-Quick-stained 
(ProSciTech) thin blood smears by light microscopy on 
day 4 p.i. and every 1–2 days after this, for the duration of 
the infection. Mice were assessed using a clinical evalu-
ation score, and CM diagnosed if mice presented with 
ruffled fur, severe motor impairment or convulsions, and 
were given a score of 3 or 4 as previously described [39]. 
P. berghei-infected mice were sacrificed at the time of CM 
(typically day 7–8 p.i.), and P. yoelii-infected mice with-
out any of the signs mentioned above were classified as 
NCM, and sacrificed at the same time, with comparable 
levels of parasitaemia of approximately 7% [24].
Blood sampling, MV purification, and brain tissue 
preparation
Mice from all biological groups were sacrificed, and 
blood and brain tissue were collected. Mouse venous 
blood was collected by retro-orbital puncture under 
anaesthesia in 0.129 mol/L sodium citrate (ratio of blood 
to anticoagulant 4:1). Platelet-free plasma (PFP) was pre-
pared as previously described [13]. PFP was then centri-
fuged at 18000g for 45 min and the supernatant removed 
and retained (MV-free plasma), while the pellet was cen-
trifuged for a further 45  min at 18000g in a solution of 
PBS and sodium citrate (ratio of PBS to anticoagulant 
3:1) to pellet MV. Whole brain tissue from each mouse 
was placed immediately in RNAzol (Molecular Research 
Centre, Inc.) and homogenized. MV, MV-free plasma, 
and homogenized brain tissue samples were stored at 
− 80 °C until RNA extraction was performed. 100 mg of 
homogenized brain tissue was used for RNA extractions, 
as per the manufacturer’s instructions. For microarray 
analysis, MV samples were pooled during vesicle purifi-
cation; all samples for RT-qPCR analysis were taken from 
individual mice and kept separate.
RNA extraction
Total RNA was extracted from pelleted MV, 0.4  mL 
MV-free plasma, and 100  mg brain tissue using the 
commercially available protocol from Molecular 
Research Centre Inc. A phase separation step using 
4-bromoanisole (MRC) was added to optimize RNA 
preparation from low amounts of starting material. All 
centrifugation steps were performed at 4 °C, and precipi-
tation was performed overnight at − 20 °C, with glycogen 
added to preserve small RNA. The concentration of RNA 
was determined using Nanodrop ND-1000 spectropho-
tometry (Nanodrop Tech), and the purity was assessed 
by calculation of the ratio of absorbance at 260 and 
280 nm, with a cut-off of 1.6 used. RNA concentrations 
of approximately 30–150, 50–300, and 3000–9000 ng/μL 
were achieved from MV, MV-free plasma, and brain tis-
sue, respectively.
cDNA synthesis and preamplification
For OpenArray analysis the starting RNA concentration 
was set at 100 ng; for RT-qPCR analysis, it was 10 ng. For 
both, preamplification was used to increase the amount 
of cDNA. cDNA synthesis and preamplification were 
performed using commercial rodent kits (Megaplex RT 
and preamplification kits) and rodent Megaplex™ Primer 
Pools for OpenArray, or custom primer pools of the 
targets of interest described below, for RT-qPCR (Ther-
moFisher Scientific).
OpenArray analysis
Pre-amplified samples were loaded onto TaqMan Ope-
nArray MicroRNA Panels to be run on the QuantStudio 
12K Flex system, as per the manufacturer’s instructions 
(ThermoFisher Scientific). 754 rodent miRNA, consist-
ing of validated mature mouse and rat miRNA (Sanger 
miRBase release v.15), were amplified in each sample, 
with technical replicates, together with internal controls. 
QuantStudio and ExpressionSuite Analysis software 
(ThermoFisher Scientific), utilizing the comparative (ΔΔ) 
 CT method, were used to quantify relative expression 
across all miRNA and samples with relative quantifica-
tion values expressed as CM/NI. Global normalization 
was performed using the global mean CT value of tar-
gets common to every sample as the normalization fac-
tor, on a per sample basis—the recommended and most 
robust strategy for normalization in large scale (> 384) 
miRNA expression profiling studies [40]. To reduce false 
positive results,  CRT (cycle of relative threshold) values 
were filtered to remove values over 30, considered not 
to be true results. In addition, technical replicates with a 
standard deviation (SD) over 0.5 between  CRT values, and 
with an amplification score below 1.2 (low quality) were 
removed. Lastly, miRNA amplified in less than 50% of 
biological replicates were considered as lowly expressed 
and excluded from the analysis. Relative quantification 
was calculated using algorithms included in the Expres-
sionSuite analysis software. Statistical calculations were 
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performed using multiple t tests—one per row, with 
fewer assumptions.
Pathway analysis
Microarray results were analyzed with DIANA miRPath 
version 3 [41] and  Ingenuity® Pathway analysis—IPA 
 (Ingenuity® System, http://www.ingen uity.com) to com-
bine filtering and miRNA matching to mRNA targets 
in order to provide insight into the potential biological 
effects of miRNA and to predict their role within tar-
get pathways. This software uses TarBase version 7 [42], 
which houses a manually curated collection of experi-
mentally tested miRNA targets. The input dataset was 
compared to all available biological pathways provided by 
the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
[43], with significantly influenced pathways identified 
(P < 0.05) and a False Discovery Rate of 5%. The database 
was searched with the full names of each murine miRNA 
as per the ThermoFisher Scientific product information 
and miRBase version 21: mmu-miR-16-1-3p, mmu-miR-
21a-3p, mmu-miR-146a-5p, mmu-miR-150-5p, mmu-
miR-193b-3p, mmu-miR-205-5p, mmu-miR-215-5p, 
mmu-miR-297a-3p, mmu-miR-328-3p, mmu-miR-
335-3p, mmu-miR-467a-5p, mmu-miR-486a-5p, mmu-
miR-685, mmu-miR-1949, and rno-miR-10b-5p.
RT‑qPCR analysis
RT-qPCR results often depend on the quality of the 
endogenous control genes chosen, ideally demonstrat-
ing gene expression that is constant and highly abundant 
across tissues and cell types, and across changing bio-
logical conditions or treatments. To verify these miRNA 
of interest highlighted by the OpenArray, four control 
miRNA (U6, Y1, sno-RNA-135, and sno-RNA-202—the 
murine miRNA from the original control panel from the 
OpenArray) were tested for their robustness of normali-
zation, and their expression across all biological groups 
and sample types. RT-qPCR analysis was performed 
using the Taqman gene expression master mix, follow-
ing recommended protocols. The starting RNA concen-
tration was set at 10  ng and each sample was tested in 
duplicate. Taqman small RNA assays for the miRNA of 
interest, i.e. hsa-miR-146a, hsa-miR-150, hsa-miR-205, 
hsa-miR-486, mmu-miR-10b, mmu-miR-193b, mmu-
miR-215, mmu-miR-467a, two miRNA amongst those 
unique to either CM or NI MV i.e. hsa-miR-590-5p and 
rno-miR-450, and the four controls were used. Repli-
cates for which the SD was > 0.5 were removed. Statisti-
cal calculations were performed using a non-parametric 
Kruskal–Wallis test, and a two-stage post hoc test to cor-
rect for multiple comparisons by controlling the False 
Discovery Rate for significant results. Results were con-
sidered significant, if P < 0.05.
Sample size calculation
A sample size calculation was performed using Graph-
Pad Statmate software v2.0. As this formula required a 
known SD, the OpenArray results were used to inform 
the calculation of a sample size necessary for subsequent 
RT-qPCR verification. A significance level (alpha) of 0.05 
(two-tailed) and a 90% power were chosen as the param-
eters for this calculation in order to increase the strin-
gency, and decrease the chance of false-positive findings 
for this verification analysis. It was found that a sample 
size of 5 in each group was sufficient to detect a signifi-
cant difference between means of ≥ 5.93.
Results
Experimental design
To examine the abundance of the miRNA cargo of MV 
released during CM, compared with NI conditions, the 
OpenArray system (ThermoFisher Scientific) was used. 
The targets of interest found in the initial screening pro-
cess were verified using qPCR analysis: examining MV, 
MV-free plasma, and brain tissue from NI, NCM and 
CM mice. miRNA of interest were evaluated in relation 
to CM pathogenesis using target prediction and pathway 
analyses. A graphical representation of the experimental 
design used is shown in Fig. 1.
Distinct profile of miRNA within MV in CM compared 
with NI mice, using array analysis
The abundance of miRNA contained in MV purified from 
PFP obtained from NI and CM CBA mice were com-
pared using  OpenArray® analysis. For microarray analy-
ses, three groups of NI mice and four groups of CM mice 
were used, with five samples pooled per group. A distinct 
abundance profile was observed in the MV from CM 
compared with NI mice. Within each biological group, 
approximately 60% of miRNA were detected in all repli-
cates within a biological group, and 408 and 361 miRNA 
were detected in > 50% of NI (blue, vertical stripes) and 
CM replicates (red, vertical stripes), respectively, and 
were therefore studied further. 431 miRNA were quanti-
fied in at least one biological group (dark grey) and 348 
miRNA were common to both biological groups (differ-
ential, light grey), while 60 and 23 miRNA were detected 
only in NI (blue) or CM MV (red), respectively (Fig. 2a).
Differentially abundant miRNA play potential roles 
in malaria infection and inflammation
miRNA that were present in > 50% of replicates within 
both NI and CM groups in the microarray analysis were 
further analyzed to identify significant miRNA of interest 
(differential miRNA from Fig. 2a, n = 348). A cut-off of ± 
twofold was used to compare the relative expression of 
these miRNA between the groups, measured as a ratio of 
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CM/NI. Figure 2b displays the results in a volcano plot, 
where miRNA common to both biological groups were 
plotted according to their fold change, and the signifi-
cance of that association. Four miRNA, shown in green, 
showed significantly decreased abundance in CM condi-
tions, and 11 miRNA (red) were significantly increased 
compared with NI conditions. These miRNA of inter-
est were further investigated and shown to have diverse 
roles defined in the literature, and using DIANA miRPath 
software. 19 pathways were significantly regulated by the 
chosen miRNA of interest, as detailed in Additional file 1: 
Table S1 and Additional file 2: Table S2, and include those 
relating to Prion diseases (P = 2.2e−20, 7 genes controlled 
by 5 miRNA in pathway), regulation of actin cytoskeleton 
(P = 0.02, 41 genes by 8 miRNA), gap junctions (P = 0.04, 
14 genes by 5 miRNA), Chagas disease (P = 0.04, 21 genes 
by 6 miRNA), and toxoplasmosis (P = 0.04, 22 genes by 
8 miRNA). Interestingly, these miRNA strongly regulate 
other neurological conditions, pathways related to MV 
formation, or other parasitic diseases, further highlight-
ing their potential importance in CM. Of the 15 miRNA 
identified by OpenArray analysis as significantly differ-
entially abundant, eight of them were chosen for verifi-
cation by RT-qPCR, according to their postulated roles 
in CM and other similar neurological or inflammatory 
Fig. 1 Experimental design. Graphical summary of the experimental design applied in the present study. PFP platelet-free plasma, MV microvesicle, 
NI non-infected, CM cerebral malaria. Images were obtained from Pixabay.com and ChemDraw (PerkinElmer)
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conditions, as well as their regulation of genes within the 
malaria pathway.
Choice of reference miRNA candidates for RT‑qPCR 
normalization
Before validating these miRNA of interest by RT-qPCR, 
potential control miRNA were assessed, in order to 
determine the best normalization strategy to be applied 
to RT-qPCR results. Four candidate controls—U6, Y1, 
sno-RNA-135, and sno-RNA-202—were investigated on 
the OpenArray results. In particular, the global normali-
zation strategy was compared to U6, and to two differ-
ent combinations—one including U6 and one not (Fig. 3), 
as the validity of U6 as a control has previously been 
debated [44]. Candidate control miRNA were deemed 
suitable if they were detected in over 70% of samples, 
and if the  CRT values fell within the range of 18–28, as 
per previous rigorous testing [45, 46], and all four ful-
filled these requirements (Fig. 3a). The number and type 
of miRNA found to be significant with the four different 
normalization strategies were then compared (Fig.  3b–
d), and increasing numbers of significant miRNA were 
observed using fewer candidate control miRNA (Fig. 3b). 
Of the 15 miRNA found to be significantly differentially 
abundant using global normalization, the numbers of 
miRNA remaining significant, decreased with the num-
bers of control miRNA used in the panel, i.e., 12 miRNA 
with 4 controls, 11 with 3 controls and 7 with U6 alone 
(Fig.  3c, d). Importantly, of the eight miRNA from this 
list of 15 that were chosen for further validation by RT-
qPCR, 7, 6 and 4 were also found to be significant when 
normalizing with the respectively listed groups above 
(Fig. 3c). Therefore, the panel of four control miRNA was 
chosen to normalize RT-qPCR verification results, as 
this strategy was found to be the most similar to global 
normalization.
Significantly changed abundance of miR‑146a 
and miR‑193b in MV following P. berghei infection
Verification by RT-qPCR was performed on newly gener-
ated samples. Seven of the 15 miRNA selected from the 
OpenArray were removed from the verification due to 
a lack of validated targets and this will be further devel-
oped in the discussion (Table 1, miR-16*, miR-21*, miR-
297a*, miR-335*, miR -328, miR-685, and miR-1949. Two 
additional miRNA—miR-590-5p and miR-450—were 
selected among those unique to either CM or NI MV for 
verification; however, as amplification was not adequate 
across all samples and biological groups, data for these 
two miRNA as well as for miR-10b, were not shown 
(Table 1). All the remaining miRNA (Table 1, miR-146a, 
miR-150, miR-193b, miR-205, miR-215, mir-467a, and 
miR-486) were tested on MV samples as per the Ope-
nArray analysis and also on MV-free plasma and brain 
tissue from NI, NCM, and CM mice. This provided a 
more comprehensive analysis of the changes occurring 
Fig. 2 Detectable miRNA profiles in MV from NI compared with CM CBA mice. a The number of miRNA quantified in one or more biological group, 
and in > 50 or 100% of replicates in each biological group are shown. miRNA present in > 50% of replicates are further separated into groups of 
those common to both biological groups (further examined in Fig. 1b) and those expressed in one biological group only. b The volcano plot 
displays miRNA present in both biological groups; for each miRNA, the fold change  (log2FC) and the significance (− log10P-value) are reported. P 
values were obtained with a student’s t test, with fewer assumptions. Horizontal threshold line: P = 0.05, a higher value indicates greater significance; 
vertical threshold lines: fold change = − 2 (left) and 2 (right). Highlighted in red are miRNA that are significantly increased in abundance in CM 
conditions, and in green, decreased
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during Plasmodium infection in order to identify those 
specific to neurological complications, in comparison to 
non-cerebral infections or non-infected status. For RT-
qPCR analysis, five mice from each of the three biologi-
cal groups were used, with each mouse representing an 
individual sample. All selected miRNA were expressed 
at detectable levels in all samples under normal physi-
ological conditions, but their expression levels after the 
inoculation of P. berghei (CM) or P. yoelii (NCM) dem-
onstrated altered abundance in 95% of cases. Signifi-
cant changes were found in the abundance of miR-146a, 
miR-193b, miR-205, miR-215, and miR-467a, as shown 
in Fig.  4. miR-146a was significantly more abundant in 
MV and MV-free plasma from mice at the time of CM 
(P = 0.027 and 0.005, respectively), compared with that 
of NI mice, and in MV-free plasma from NCM mice 
compared with NI mice (P = 0.012), while no significant 
differences were observed in the brain samples. In MV 
samples only, miR-193b was less abundant at the time of 
CM, compared with both NI (P = 0.007) and NCM con-
ditions (P = 0.007) (Fig.  4). The significant changes in 
miRNA abundance in MV reflected the findings of the 
OpenArray. Specifically, miR-146a and miR-193b were 
both significantly dysregulated in the MV from CM mice 
compared with NI-increasing 3.2- or 7.2-fold in the case 
of miR-146a, or decreasing 2.7- or 7.5-fold (miR-193b) 
in array and RT-qPCR analysis, respectively (Table  1). 
miR-467a was significantly less abundant in the MV-
free plasma from CM mice (P = 0.050) and NCM mice 
(P = 0.020) compared with NI (Fig. 4). Interestingly, dif-
ferent profiles were observed in the brain samples: miR-
205, miR-215, and miR-467a were significantly increased 
abundance in the brains of CM mice compared with NI 
(P = 0.011, 0.016, and 0.015 respectively), but no change 
was observed in the brains of NCM mice (Fig. 4).
No significant change in the abundance of miR‑150, 
miR‑205, miR‑215, miR‑467a, and miR‑486 in MV 
following Plasmodium infection
Of the seven miRNA of interest tested by RT-qPCR, miR-
146a and miR-193b showed the same significant change 
in abundance as in the OpenArray (from Fig. 2b). A fur-
ther four miRNA—miR-150, miR-215, miR-467a, and 
miR-486 showed the same directional change in abun-
dance as in the OpenArray analysis, without reaching 
significance (Fig. 4). Comparative results for the miRNA 
of interest for the OpenArray and RT-qPCR analyses are 
displayed in Table  1. miR-205 showed a small decrease 
in abundance in the RT-qPCR validation experiments, 
compared to the significantly increased abundance in the 
OpenArray analysis. miR-10b, results were not shown, 
due to poor RT-qPCR amplification across all sam-
ple types. The direction of regulation in CM conditions 
was the opposite for MV and brain tissue in the case of 
Fig. 3 Assessing normalization strategies for miRNA relative quantification. Four candidate controls were used to normalize OpenArray results in 
two different combinations—one including U6 and one not, as well as U6 alone; and compared to the global normalization used for OpenArray 
analysis. a Each candidate control was assessed individually in terms of percentage detection and mean  CRT of candidate controls across all samples 
and biological groups tested using the OpenArray system, These candidate controls were also assessed across the four normalization strategies 
in terms of b number of significant miRNA, and further to this c significant miRNA from global normalization that were also significant with other 
normalization strategies, and, of those significant and common miRNA, how many from the list of those chosen for further validation by RT-qPCR. d 
Venn Diagram shows the overlap between statistically significant miRNA as determined by all normalization methods
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miR-150, miR-205, miR-193b, and miR-467a. For these 4 
miRNA as well as miR-146a, the direction of regulation 
in CM conditions was the same for MV and MV-free 
plasma. In all cases within the brain samples—except 
miR-150—miRNA abundance increased (significantly or 
not, in the case of specific miRNA) in CM compared with 
NI and NCM conditions, with NCM being an interme-
diate abundance level between the other two biological 
groups. This intermediate abundance in NCM conditions 
was applicable in almost all miRNA tested in MV and 
MV-free plasma samples as well.
Significantly differentially abundant miRNA regulate genes 
with identified roles during malaria infection
Of the differentially abundant miRNA from the Ope-
nArray analysis that were further analyzed by RT-qPCR, 
five significantly abundant miRNA regulate genes within 
the KEGG malaria pathway (Fig.  5). This figure sum-
marizes the changes occurring during malaria infec-
tion at the gene level, and the impact this has on various 
cell types and molecules produced. This figure has been 
revised from the original KEGG pathway, with genes 
involved highlighted based on the miRNA of inter-
est and their roles in regulating these genes. Within the 
malaria pathway, a collection of miRNA specifically regu-
late the groups of genes surrounding MV release, regu-
lation of inflammatory cytokines, and cytoadherence of 
cells to the vascular endothelium. To summarize, three 
miRNA: miR-146a, miR-193b, and miR-467a, control 10 
genes within the malaria pathway: CD40 ligand (CD40L, 
CD154), CXCL8 (IL-8), IFNγ, Integrin β2 (ITGβ2), 
Transforming Growth Factor β2 (TGFβ2), Thrombos-
pondin genes (THBS1/TSP1, THBS2/TSP2), Toll-Like 
Receptors (TLR2, TLR4), and TNF. Further to this, many 
of these miRNA also have roles defined in the literature, 
relating to similar neuro-inflammatory conditions (more 
detail in Additional file 1: Table S1).
Discussion
As miRNA research has expanded into numerous dis-
ease areas, it has become clear that expression levels of 
certain miRNA are altered in many diseases, includ-
ing malaria [20, 24, 26]. However, despite these studies 
examining miRNA during malaria infection, the mecha-
nism of action of miRNA and whether they play a path-
ogenic or immuno-protective role is still unclear. This 
study describes for the first time, the changes in miRNA 
content of MV during Plasmodium infection in mice and 
shows a clear dysregulation of miRNA abundance within 
circulating MV during experimental CM as compared 
with non-infected and non-CM mice.
In mice, P. berghei infection triggers an intricate series 
of events that leads to CM, including an increased release 
of extracellular vesicles, released from EC, platelets, and 
RBCs [12, 13]. miRNA have also been implicated in this 
process by actively regulating the immune or inflam-
matory response. In fact, many studies have shown that 
miRNA constitute a key mechanism by which MV medi-
ate cellular communication. Specifically, during malaria 
infections, miRNA from pRBC MV have been shown to 
modulate EC permeability, affecting vascular function 
[27]. Furthermore, evidence of changed miRNA lev-
els in the brains of mice with CM compared with NCM 
or NI mice has been reported [24, 26]. Using OpenAr-
ray technology as a screening approach, 754 miRNA 
targets were assessed and 15 miRNA with significantly 
dysregulated abundance in MV from CM mice in com-
parison to NI mice were detected. To verify the screened 
results, and to better understand miRNA changes during 
the severe infection, eight of these targets were selected 
and their abundance measured by RT-qPCR in MV, MV-
free plasma, and brain tissue from CM and NI mice. The 
remaining seven miRNA were not tested as they had no 
validated murine targets following IPA analysis and/or 
few or no publications were available examining them. 
Table 1 Choice of  targets for  validation by  RT-qPCR 
from OpenArray analysis
The list of significantly differentially expressed miRNA in CM vs NI MV from 
the OpenArray analysis was compared with the results obtained by RT-qPCR 
analysis. Results presented as relative quantification ± SEM
P: * = 0.05–0.01, ** = 0.01–0.0001, *** ≤ 0.0001
a miRNA not validated by RT-qPCR due to lack of relevance to this study
b miRNA not validated despite being tested by RT-qPCR due to technical issues
c Large SEM variation due to outliers in NI and CM MV groups
miRNA Significance of fold change in CM vs. 
NI MV
OpenArray RT‑qPCR
hsa-miR-328 − 2.5* ± 0.93 Not  testeda
hsa-miR-335* − 3.0* ± 1.13 Not  testeda
mmu-miR-16* 2.8** ± 0.65 Not  testeda
mmu-miR-21* 5.0** ± 0.88 Not  testeda
mmu-miR-297a* 5.8* ± 1.60 Not  testeda
mmu-miR-685 3.0* ± 1.00 Not  testeda
mmu-miR-1949 5.0* ± 1.69 Not  testeda
hsa-miR-590-5p Unique to NI Not  validatedb
rno-miR-450 Unique to CM Not  validatedb
mmu-miR-10b 2.7* ± 0.85 Not  validatedb
hsa-miR-146a 3.2** ± 0.68 7.2* ± 2.74
hsa-miR-150 1.8* ± 0.64 2.7 (ns) ± 2.26
hsa-miR-205 2.3* ± 0.75 − 0.5 (ns) ± 1.89
hsa-miR-486 2.3*** ± 0.18 4.7 (ns) ± 1.45
mmu-miR-193b − 2.7** ± 0.62 − 7.5* ± 0 62
mmu-miR-215 2.1* ± 0.55 4.6 (ns) ± 99.39c
mmu-miR-467a − 2.0* ± 0.69 − 5.6 (ns) ± 0.96
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In contrast, the remaining miRNA of interest chosen for 
RT-qPCR verification did have validated murine targets, 
as well as relevant roles related to neuropathologies and 
inflammatory conditions similar to CM (Additional file 2: 
Table S2). To assess the results regarding their specificity 
to the malarial neurological syndrome, samples obtained 
from NCM mice were also analyzed.
Upon verification, two miRNA were confirmed as sig-
nificantly dysregulated in CM MV: miR-146a and miR-
193b, suggesting a role for these miRNA in cerebral 
pathology, as the same significant changes were not 
observed in NCM mice [47]. miR-146a was significantly 
over-abundant in CM MV and MV-free plasma com-
pared to NI, but not in brain tissue—although the same 
trend in abundance shift was observed. An increased 
abundance of miR-146a is triggered by inflammatory fac-
tors including IL-1 and TNF [48], and dysregulates sev-
eral targets, the majority of which are involved in toll-like 
receptor pathways, triggering a cytokine response, or in 
the innate immune system [48, 49], and these changes are 
also observed in CM [50]. Within the malaria pathway, 
miR-146a suppresses the CD40L, CXCL8, IFNγ, TLR2, 
TLR4, and ITGβ2 genes. Together with miR-155 and 
miR-21, miR-146a operates in a negative feedback loop 
to specifically calibrate inflammatory responses [51]. The 
role this miRNA plays within inflammatory conditions 
[49] has been researched extensively, identifying miR-
146a as a biomarker for sepsis [52] and prion infections 
[53]. Notably, in the latter, miR-146a was part of a 
miRNA signature within exosomes from prion-infected 
neuronal cells. Finally, miR-146a has also been implicated 
in the overactive response to infection, therefore has pre-
viously been proposed to have potential as a therapeutic 
target [54].
Remarkably, miR-193b was significantly decreased in 
CM MV as compared not only to NI, but also NCM MV. 
Critically, no similar significant difference was observed 
in the MV-free plasma or brain tissue, though the oppo-
site trend in abundance shift was observed in the latter. 
miR-193b plays a role in the TGFβ2 signaling pathway 
[55], and in monocyte-macrophage differentiation [56], 
both of which have been explored in relation to CM [50]. 
Within the malaria pathway, miR-193b promotes the 
THBS1, THBS2, and TGFβ2 genes; and regulates apop-
tosis by targeting myeloid leukaemia cell differentiation 
protein 1, among others [57]. Notably, miR-193b is a pre-
dictor of mortality in several other severe inflammatory 
conditions with associated neurotropic complications. 
Specifically, miR-193b is decreased in abundance in 
amyotrophic lateral sclerosis [58], and in sepsis [59], for 
which it has been identified as a biomarker.
Interestingly, miR-146a and miR-467a were signifi-
cantly increased and decreased, respectively, in both 
CM and NCM MV-free plasma compared to NI. There-
fore, these miRNA are likely to be indicative of a severe 
malaria infection, rather than specific to neurological 
Fig. 4 Changes in abundance of miRNA of interest in MV, MV-free plasma and brain tissue. Dot plots show the expression levels of miR-146a, 
miR-193b, miR-205, miR-215, miR-467a, miR-150, and miR-486 measured for MV, MV-free plasma, and brains from NI, NCM, and CM conditions, 
expressed as normalized values as compared to the expression of a panel of control miRNA in each case. The results are presented as follows: 
significant changes in MV – miR-146a and miR-193b, significant changes in the brain—miR-205, miR-215, and miR-467a, no significant changes—
miR-150 and miR-486. miR-146a and miR-467a also showed significant changes in the MV-free plasma. The horizontal line denotes the mean value, 
and the error bars denote SEM. A nonparametric Kruskal–Wallis test was carried out. If the Kruskal–Wallis test was significant, post hoc tests—Dunn’s 
multiple comparisons test—were carried out. The results of these are denoted as * = 0.05–0.01, ** = 0.01–0.0001, *** ≤ 0.0001
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complications. In contrast to the changes observed in 
MV, miR-205, miR-215, and mir-467a were increased 
only in the brains of CM compared with NI mice, or 
NCM mice. These data support the observation that par-
ticular miRNA may be detectable only in specific sam-
ples, suggesting a preferential expression from specific 
cell types [60, 61].
The differences in abundance profiles observed in the 
three different sample types analyzed provide further 
evidence that miRNA appear to be selectively expressed 
in the circulation, whether in the MV-free plasma itself, 
or expressed on the surface of or packaged within circu-
lating MV. Specifically, the directional change in abun-
dance of these miRNA of interest in MV-free plasma 
in CM conditions more closely reflected the changes 
within MV, compared with the opposite changes within 
brain tissue. In examining further the brain, all but 
one miRNA (miR-150) showed increased abundance 
in the brains of CM mice, as compared with their NI 
Fig. 5 Malaria KEGG pathway. DIANA mirPath v.3 and Tarbase v.7 were used to compile lists of genes controlled by significantly differentially 
expressed miRNA tested using OpenArray analysis and verified by RT-qPCR analysis. Following this, the KEGG pathway for genes known to be 
involved in malaria infection was modified to show the role played by these miRNA. Permission has been granted for reproduction of this image. 
NB: some genes, including LFA1, IL8, TGFβ, and TSP are listed in the original KEGG pathway, but have been changed here to alternative but 
equivalent names—ITGB2, CXCL8, TGFβ2, and THBS respectively, as these gene names reflect those in the lists for the specific miRNA analyzed
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counterparts; interestingly their NCM counterparts 
demonstrated intermediate levels of expression, further 
demonstrating the difference in the degree of in sever-
ity between the two infections.
In line with previous studies comparing plasma or 
serum, and MV, MV-free plasma samples showed a 
more variable expression pattern for the miRNA of inter-
est [62]. With the MV portion of the MV-free plasma 
removed, remaining miRNA are likely to be stable circu-
lating extracellular miRNA secreted from cells, or pre-
sent in other types of vesicles not tested in the current 
analysis—such as exosomes, as both of these sources 
have previously been identified in other diseases or con-
ditions [27, 63]. Previous studies have identified miRNA 
present in a range of fluids and biological specimens or 
tissue types. Among these profiles, some highly abundant 
miRNA were common to multiple sample types, while 
others were enriched only in particular conditions [61], 
and the same phenomenon was observed in this study. 
The difference in abundance of particular miRNA in 
particular sample types here indicates the variety of the 
roles played by certain miRNA in specific locations or 
conditions.
Those miRNA validated by RT-qPCR and displaying 
significant differences in abundance during CM com-
pared with NI conditions were examined within the 
KEGG pathway for malaria (Fig. 5), which highlights evi-
dence of miRNA regulation relating to many of the criti-
cal components in CM development. Specifically, during 
severe Plasmodium infection, miR-146a and/or miR-
193b regulate functions such as production of inflamma-
tory cytokines (also involving miR-467a), recruitment of 
macrophages, increased nitric oxide production, disrup-
tion of neuronal function, as well as modulation of the 
expression of surface molecules controlling interactions 
between circulating cells and endothelial cells [4, 64].
Of importance to this work are the recent improve-
ments in the understanding of the role of miRNA in the 
regulation of molecular and cellular networks associ-
ated with inflammation [65]. Consequentially, miRNA 
potential as biomarkers of inflammatory processes and 
infectious diseases has become increasingly evident 
[65]. In this context, further investigations of miRNA 
contained in MV (such as miR-146a and miR-193b) or 
circulating in the MV-free plasma (such as miR-146a 
and miR-467a), as well as the remaining miRNA of 
interest from the OpenArray not yet verified by RT-
qPCR, such as miR-328 and miR-335*, are necessary to 
assess whether these miRNA are biomarkers of sever-
ity or mortality. Detailed examination of the kinetics of 
these miRNA in MV over the course of infection could 
reveal novel candidate markers for the early progno-
sis or diagnosis of CM. Furthermore, the evaluation of 
their abundance in human paediatric samples as well as 
functional studies using in  vitro CM models to estab-
lish their cellular source and targets, will help to under-
stand the clinical potential of these miRNA and their 
role in CM pathogenesis. It is also important to note 
that the OpenArray identified a significant number of 
miRNA expressed only in CM or NI MV, that warrant 
further investigation as to their biological relevance. 
In investigating for the first time the miRNA content 
of murine MV during CM, these results indicate that 
the content of plasma MV is affected during the severe 
infection and should be considered in the understand-
ing of CM pathogenesis.
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